Research involving human genetic or genomic information analyzed in conjunction with other personal or health data has become increasingly important for understanding risk factors underlying complex (multi-factorial) diseases. Such research is critical to improve detection, prevention, diagnosis and treatment.

A first wave of large-scale, high-density genome-wide association (GWAS) studies has been reported which improved our understanding of the genetic basis of many complex traits, including type 1 and type 2 diabetes, hypertension, dyslipidemias, coronary heart disease, atrial fibrillation, inflammatory bowel disease, prostate cancer, breast cancer, asthma.

Medpharmgene with its partners Prognomix and Biogenix has a unique capability to perform clinical trials using information from genetic, genomic and epigenetics assays, and to analyze these data in conjunction with clinical data generated from either available databases or prospective clinical studies. - canadian online casinos